Patents by Inventor Sridhar K. Rabindran

Sridhar K. Rabindran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272
    Patent number: 10729672
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: August 4, 2020
    Assignee: Wyeth LLC
    Inventors: Laurence Moore, Charles Zacharchuk, Sridhar K. Rabindran
  • Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272
    Publication number: 20120308560
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: April 24, 2012
    Publication date: December 6, 2012
    Applicant: Wyeth LLC
    Inventors: Laurence Moore, Charles Zacharchuk, Sridhar K. Rabindran
  • ANTINEOPLASTIC COMBINATIONS WITH mTOR INHIBITOR, TRASTUZUMAB, AND/OR HKI-272
    Publication number: 20090297519
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: August 12, 2009
    Publication date: December 3, 2009
    Applicant: Wyeth
    Inventors: Laurence Moore, Charles Zacharchuk, Sridhar K. Rabindran
  • Antineoplastic combinations comprising
    Patent number: 6617333
    Abstract: This invention provides the use of a combination of CCI-779 and EKB-569 in the treatment of neoplasms.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: September 9, 2003
    Assignee: Wyeth
    Inventors: Sridhar K. Rabindran, James J. Gibbons, Jr.
  • Antineoplastic combinations
    Publication number: 20030050222
    Abstract: This invention provides the use of a combination of CCI-779 and EKB-569 in the treatment of neoplasms.
    Type: Application
    Filed: August 6, 2002
    Publication date: March 13, 2003
    Applicant: Wyeth
    Inventors: Sridhar K. Rabindran, James J. Gibbons
  • Treatment of neoplasms with CCI-779/EKB-569 combination
    Patent number: RE40418
    Abstract: This invention provides the use of a combination of CCI-779 and EKB-569 in the treatment of neoplasms.
    Type: Grant
    Filed: September 8, 2005
    Date of Patent: July 1, 2008
    Assignee: Wyeth
    Inventors: Sridhar K. Rabindran, James J. Gibbons, Jr.